Kaye, Donald
April 2004
Clinical Infectious Diseases;4/1/2004, Vol. 38 Issue 7, piv
Academic Journal
Reports a new class of antiretroviral drugs that prevent HIV from infecting cells. Advantages of the drug; Details of SCH-D, an antagonist of the CCR5 coreceptor, as provided by Mark Laughlin and colleagues of Schering-Plough Research Institute in Kenilworth, New Jersey at the 11th Annual Retrovirus Conference; Submission of preliminary data for BMS-488043 by Bristol-Myers Squibb.


Related Articles

  • Taking Biomarkers into the Clinic. Shaffer, Catherine // Drug Discovery & Development;Jun2006, Vol. 9 Issue 6, p60 

    The article discusses the utilization of biomarkers in clinical research and development. Joseph Ahearn, co-director of the Lupus Center of Excellence at the University of Pittsburgh introduced a new set of biomarkers for monitoring the progression of lupus. Bristol-Myers Squibb is using genetic...

  • Experiencing antiretroviral adherence: helping healthcare staff better understand adherence to paediatric antiretrovirals. Phelps, Benjamin R.; Hathcock, Sarah J.; Werdenberg, Jennifer; Schutze, Gordon E. // Journal of the International AIDS Society;2010, Vol. 13 Issue 1, p1 

    Background: Lack of adherence to antiretroviral medications is one of the key challenges for paediatric HIV care and treatment programmes. There are few hands-on opportunities for healthcare workers to gain awareness of the psychosocial and logistic challenges that caregivers face when...

  • Diseases in the Third World Challenge Manufacturers. Wechsler, Jill // Pharmaceutical Technology;Oct2005, Vol. 29 Issue 10, p36 

    Focuses on challenges in manufacturing fixed-dose combination drugs for AIDS patients in developing countries. Need for expansion of manufacturing operations to meet demands for AIDS drugs; Meeting of worldwide regulatory standards; Problems of Bristol-Myers Squibb in meeting demand for...

  • Bristol-Myers Squibb and the Medicines Patent Pool – An Unlikely Marriage? Chu, Rachel // European Journal of Risk Regulation;2014, Vol. 5 Issue 1, p68 

    The article reports on the agreement of pharmaceutical Bristol-Myers Squibb with the Medicines Patent Pool (MPP) to license atazanavir, an antiretroviral (AVR) drug. It says that the agreement adds an important compound to the arsenal of treatments for HIV/AIDS and strengthen the defence of...

  • Welcoming Atripla. McManus, Michael // Advocate;8/29/2006, Issue 969, p47 

    The article reports on the approval of the antiretroviral HIV/AIDS drug Atripla from Bristol-Mayers Squibb by the U.S. Food and Drug Administration. When the first antiretroviral HIV/AIDS drugs were approved by the Food and Drug Administration 10 years ago, many patients were taking more than 20...

  • Report from: Brazil. Berger, Hellen // Pharmaceutical Technology Europe;Jan2013, Vol. 25 Issue 1, p20 

    The article focuses on an agreement between Bristol-Myers Squibb Co. and the health ministry of Brazil for developing the antiretroviral drug atazavanir sulfate locally in Brazil. It informs that the developed drug is used for treating HIV-infected patients and will be produced at a Rio de...

  • Changing of the guard in HIV treatment.  // PharmaWatch: Monthly Review;May2007, Vol. 6 Issue 5, p28 

    The article focuses on various antiretroviral agents used for the treatment of HIV infections. The drug Atripla combines the components of highly active antiretroviral therapy (HAART). It has been developed through a collaboration between the firms Gilead and Bristol-Myers Squibb Co. The drugs...

  • Barr Says FDA Approves Generic Version of Anti-HIV Drug.  // Clinical Infectious Diseases;1/15/2005, Vol. 40 Issue 2, preceding p1 

    This article reports that Barr Pharmaceuticals Inc. on Friday said the Food and Drug Administration approved the company's generic version of Videx EC, an antiretroviral drug developed by Bristol-Myers Squibb Co.

  • Combination drug for HIV.  // Cortlandt Forum;Oct2006, Vol. 19 Issue 10, p18 

    The article offers information about Atripla, an antiretroviral agent, from Bristol-Myers Squibb Co. and Gilead. The drug is a combination of three anti-HIV drugs which includes Sustiva, Emtriva and Viread. Furthermore, Atripla was approved by the Food and Drug Administration based on clinical...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics